Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

3.96USD
21 Nov 2018
Change (% chg)

$-0.07 (-1.74%)
Prev Close
$4.03
Open
$3.98
Day's High
$3.98
Day's Low
$3.96
Volume
500
Avg. Vol
3,672
52-wk High
$13.50
52-wk Low
$3.70

Summary

Name Age Since Current Position

Nuriel Kasbian

58 2013 Chairman of the Board

Shai Yarkoni

58 2013 Chief Executive Officer, Director

Eyal Leibovitz

55 2017 Chief Financial Officer

Amotz Nehushtan

56 2016 Vice President - Research & Development & Product Development

Yaron Pereg

2017 Chief Development Officer

Guy Sapir

49 2016 Internal Auditor

Ruth Ben Yakar

47 2014 Director

Michael Berelowitz

71 2017 Director

Yuval Berman

50 2009 External Director

David Grossman

43 2014 External Director

Abraham Nahmias

63 2014 Independent Director

Biographies

Name Description

Nuriel Kasbian

Mr. Nuriel Chirich Kasbian, (known as Chirich), serves as Chairman of the Board at Cellect Biotechnology Ltd since July 4, 2013. Prior to this role, he served as Director at the Company (July 1, 2013-July 4, 2013). He is the Founder and General Manager of Kasbian- LeadCom Tanzania, which operates in East Africa for the past 15 Years. Mr. Kasbian is The Honorary Consul of Tanzania in Israel.

Shai Yarkoni

Dr. Shai Yarkoni serves as Chief Executive Officer and Director at Cellect Biotechnology Ltd since July 4, 2013. Prior to this, he served as Director at the Company (from July 1, 2013). He is also the Founder of the Company. Dr. Yarkoni has over 15 years of clinical and management experience in the Biopharmaceutical industry. He has founded 5 Start-Up companies in the Life-Sciences sector. He holds a Doctorate of Medicine degree and a Doctorate in Philosophy degree, both from The Hebrew University of Jerusalem.

Eyal Leibovitz

Mr. Eyal Leibovitz has been appointed Chief Financial Officer at Cellect Biotechnology Ltd effective January 1, 2017. His work experience includes the following roles: Chief Financial Officer at Evogene Ltd, Chief Financial Officer and member of the executive committee at N-trig Ltd., Chief Financial Officer at Kamada Ltd. (2007-2011) and International Controller of Harmonic Inc. (2002-2007). He holds a Bachelor of Business Administration degree from City University of New York.

Amotz Nehushtan

Dr. Amotz Nehushtan serves as Vice President - Research & Development and Product Development at Cellect Biotechnology Ltd since May 2, 2016. Until this date, he held the role of Vice President-Product Development at the Company since July 19, 2015. His work experience includes the following roles: Chief Executive Officer at Ilutan Ltd. (three and a half years) and Vice President - Research & Development at Target-in and at Pharmaseed. He holds a Doctorate of Science degree in Biochemistry from The Hebrew University of Jerusalem.

Yaron Pereg

Dr. Yaron Pereg has been appointed Chief Development Officer at Cellect Biotechnology Ltd effective January 30, 2017. He has a diverse experience in Pharma and Biotech Research and Development, including preclinical, regulatory, clinical, CMC and operational activities of drug development in the field of oncology. His work experience includes the following roles: Senior Director of Oncology at BioLineRx and Research and Development roles at Genentech Inc. and at Glusense.

Guy Sapir

Mr. Guy Sapir serves as Internal Auditor at Cellect Biotechnology Ltd since May 31, 2016. His work experience includes the role of Partner-Internal Auditing Services at Kesselman & Kesselman C.P.A.s-PWC Israel for 11 years. He holds a Masters degree in Accounting and Economics from Tel Aviv University. He is a Certified Chartered Accountant.

Ruth Ben Yakar

Dr. Ruth Ben Yakar serves as Director at Cellect Biotechnology Ltd since July 31, 2014. Her work experience includes the following roles: Chief Executive Officer at BioSight, Chief Executive Officer at Procognia (Israel) Ltd (two years), Vice President-Projects Management at Gamida Cell (two years), Chief Business Officer at YEDA (The Technology Transfer Company of Weizmann Institute of Science; two years) and Director at IATI-Israel Advance Technologies Industries. She holds a Bachelor of Science degree in Biology from Tel Aviv University and a Doctorate of Science degree in Molecular Biology from Weizmann Institute of Science.

Michael Berelowitz

Dr. Michael Berelowitz has been appointed Director at Cellect Biotechnology Ltd effective March 2, 2017. Dr. Berelowitz has over 40 years of clinical development and academic research experience, including 5 years of pharmaceutical development experience with Pfizer, Inc. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. Dr. Berelowitz serves as a biopharmaceuticals consultant. He holds Directorship Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes. Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.

Yuval Berman

Mr. Yuval Berman serves as External Director at Cellect Biotechnology Ltd since August 27, 2009. His work experience includes the following roles: Owner, Founder and Managing Director of U.V.B Business Initiatives Ltd. He holds a Bachelors degree in Economics and Law from Tel Aviv University and a MBA degree from Solvay Business School, ULB, Brussels.

David Grossman

Mr. David Grossman serves as External Director at Cellect Biotechnology Ltd since November 9, 2014. His work experience includes the following roles: Chief Executive Officer and Director at XTL Biopharmaceuticals Ltd (five years), Director at Intercure Ltd (18 months), Director at Proteologics Ltd (one year), Director at Biolight Life Sciences Ltd (two and a half years) and External Director at GFC Green Fields Capital Ltd (three years. Mr. Grossman holds a Bachelors degree in Business Administration from The Interdisciplinary Center (IDC) Herzliya.

Abraham Nahmias

Mr. Abraham Nahmias serves as Independent Director at Cellect Biotechnology Ltd since July 31, 2014. His work experience includes the role of Accountant at a private Accountancy firm for 30 years and he holds Directorship at a variety of companies. He holds a Bachelors degree in Accounting and Economics from Tel Aviv University. He is a Certified Public Accountant.